



Leksell Gamma Knife[®] Icon[™]

An exceptional tool for exceptional neurosurgery



What's important to your clinic to meet this need?

Increased patient throughput



✓

Expand clinical scope



✓

System reliability



✓

Flexible workflows




✓

Leading rapid advances in SRS

Majority of current SRS guidelines are primarily based on recommendations on Gamma Knife evidence


Vestibular Schwannoma



97%

of all single session SRS articles
are Gamma Knife publications

Trigeminal Neuralgia



70%


of studies

88%

of patients

treated on Gamma Knife

AVMs



75%

of studies

95%

of patients

treated on Gamma Knife


Leksell Gamma Knife

Leading rapid advances in intracranial SRS/SRT

Unparalleled clinical evidence:

3x more

publications* than all other technologies combined



Leksell Gamma Knife

Undisputed clinical and scientific dominance



~90k

patients treated annually



>345

Gamma Knife systems
in clinical use



>1.3M

patients treated til 2019¹



>10k

peer-reviewed LGK
publications on PubMed²

With the support of




LEKSELL
GAMMA KNIFE
SOCIETY

Leksell Gamma Knife Society



Founded

30 years ago




Aims to drive
education, research
and collaboration



Indications treated

> 60




Annual
treatment
statistics



LGKS members


> 1800



Peer-to-peer
collaboration
and knowledge
sharing

Leksell Gamma Knife epidemiology as of 2020

		Annual Incidence (per million)	% indicated for Gamma Knife treatment	Annual Gamma Knife cases (per million)
Vascular Malformations	Arteriovenous Malformations	8.9–13.4 ¹⁻³	70	6.2–9.4
	Cavernous Malformations	1.5–5.6 ⁴	15	0.2–0.84
Functional Disorders	Trigeminal Neuralgia	126–289 ⁶⁻⁷	50	63–144.5
	Essential Tremor	237 ⁸	50	118.5
Benign Tumors	Meningioma	86 ¹¹	50	43
	Pituitary Adenoma	40.1 ¹¹	15	6
	Vestibular Schwannoma	20 ¹¹	80	16
	Craniopharyngioma	1.3 ¹²	20	0.26
Malignant Tumors	Metastases	300–500 ¹³⁻¹⁴	90	270–450
	Glioblastoma Multiforme	32 ¹¹	20	6.4
	Uveal Melanoma	5.1 ¹⁵	40	2.04
TOTAL				532–798



Build a strong business case

High patient throughput



512

average patients/year*



> 1000

throughput potential per year



99%


average uptime**



< 10 min

QA time per day

Uptime



Patient throughput



* LGK Society annual treatment statistics 2019
** With a valid service agreement

Gamma Knife referral mapping

By indications

